The following ventures have been selected by the
INCATE Selection Committee
INVITRIS
Invitris developed the worldwide first platform technology to synthesize arbitrary phages within a single system, thus enabling full scalability of therapeutic phage isolation, modification, production, and application.
Myxobiotics
Myxobiotics is a start-up company discovering and developing novel antibiotics from natural products first isolated and characterized from myxobacteria.
smartbax
At smartbax we develop novel multi-targeted, antibacterial compounds with extraordinary potency against multi-drug resistant bacteria and difficult-to-treat biofilms.
The following ventures were selected
at INCATE pitch events
Limmatech Biologics
LimmaTech Biologics AG is a clinical stage biopharmaceutical company focused on the development and manufacture of next generation vaccines for the prevention of life-threatening diseases.
